UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)
NeoTherapeutics, Inc.
(Name of Issuer)
COMMON STOCK, $.001 par value per share
(Title of Class of Securities)
640-656104
(CUSIP Number)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13d-1(b)
[_] Rule 13d-1(c)
[X] Rule 13d-1(d)
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act,
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13G/A
--------------------- -----------------
CUSIP No. 640-656104 Page 2 of 5 Pages
--------------------- -----------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS/
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Alvin J. Glasky, Ph.D.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS)
N/A (a) [_]
(b) [_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
--------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 1,864,498/1/
-----------------------------------------------------
REPORTING 6 SHARED VOTING POWER
BENEFICIALLY 0
-----------------------------------------------------
OWNED BY 7 SOLE DISPOSITIVE POWER
EACH 1,864,498/1/
-----------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,864,498 /1/
--------------------------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [_]
(See Instructions)
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.6%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
IN
--------------------------------------------------------------------------------
Item 1.
(a) Name of Issuer: NeoTherapeutics, Inc.
--------------
(b) Address of Issuer's Principal Executive Offices:
-----------------------------------------------
157 Technology Drive
Irvine, California 92618
Item 2.
(a) Name of Person Filing: Alvin J. Glasky, Ph.D.
---------------------
(b) Address of Principal Business Office:
------------------------------------
157 Technology Drive
Irvine, California 92618
(c) Citizenship: United States of America.
-----------
(d) Title of Class of Securities: Common Stock, $.001 par value per share
----------------------------
(e) CUSIP Number: 640-656104
------------
Item 3.
If this statement is filed pursuant Rule 13d-1(b), or 13d-2(b), check
whether the person filing is a:
(a) [_] Broker or dealer registered under Section 15 of the Act;
(b) [_] Bank as defined in Section 3(a)(6) of the Act;
(c) [_] Insurance Company as defined in Section 3(a)(19) of the Act;
(d) [_] Investment Company registered under Section 8 of the Investment
Company Act;
(e) [_] Investment Advisor registered under Section 203 of the
Investment Advisors Act of 1940;
(f) [_] Employee Benefit Plan, Pension Fund which is subject to the
provisions of the Employee Retirement Income Security Act of 1974
or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)
(g) [_] Parent Holding Company, in accordance with Rule 13d-1(b)(ii)(G)
(Note, See Item 7);
(h) [_] Group, in accordance with Rule 13d-1(b)(1)(ii)(H).
If this statement is filed pursuant to 13d-1(c), check this box. [_]
Item 4. Ownership.
(a) Amount beneficially owned: 1,864,498/1/ shares of Common Stock
(b) Percent of Class: 7.6%
(c) Number of shares as to such person has:
(i) sole power to vote or to direct the vote of: 1,864,498/1/
(ii) shared power to vote or to direct the vote of: 0
(iii) sole power to dispose or to direct the disposition of:
1,864,498/1/
(iv) shared power to dispose or to direct the disposition of: 0
Item 5. Ownership of 5% or Less of Class.
If this statement is being filed to report the fact that as of the date
hereof the reported person has ceased to be the beneficial owner of more than 5%
of the class of securities, check the following: [_]
Item 6. Ownership of More Than 5% on Behalf of Another Person
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
Not applicable.
--------------
/1/ Includes 707,500 shares which can be acquired upon the exercise of
outstanding options within 60 days of February 12, 2002 and 4,000 shares in the
NeoTherapeutics, Inc. 401-K Plan held by the Reporting Person. Also includes
23,149 shares owned by the Reporting Person's wife and 28,750 shares which can
be acquired by the Reporting Person's wife upon the exercise of outstanding
stock options within 60 days of February 12, 2002.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: February 13, 2002 /s/Alvin J. Glasky
-----------------------------------------
Name: Alvin J. Glasky, Ph.D.